Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%
A Pilot Prospective Clinical Trial to Evaluate the Efficacy and Safety of Large-Scale, Field-Directed Topical Therapy of Actinic Keratosis of the Chest With Ingenol Mebutate 0.015%
Sponsor: Goldman, Butterwick, Fitzpatrick and Groff
Listed as NCT02446223, this PHASE4 trial focuses on Actinic Keratosis and remains completed. Sponsored by Goldman, Butterwick, Fitzpatrick and Groff, it has been updated 10 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Oct 2019 [monthly]
Completed PHASE4
-
Mar 2017 — Jun 2018 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Goldman, Butterwick, Fitzpatrick and Groff
- LEO Pharma
For direct contact, visit the study record on ClinicalTrials.gov .